Polyarteritis nodosa epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(12 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Polyarteritis nodosa}}
{{Polyarteritis nodosa}}
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
{{CMG}}{{APM}} {{AE}} {{SSW}}


{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}; [[User:Haritha|Haritha Machavarapu, M.B.B.S.]]
==Overview==
==Overview==
The [[incidence]] of polyarteritis nodosa is approximately 3 to 4 per 100,000 individuals worldwide.The  [[prevalence]] among alaskan population suffering with [[hepatitis B]] infection is approximately 7.7 per 100,000 individuals.Patients of all age groups may develop polyarteritis nodosa.There is no racial predilection to polyarteritis nodosa.Males are more commonly affected by polyarteritis nodosa than females.Population prevalence estimates for polyarteritis nodosa (PAN) range from 2 to 33 per million across the European Countries.
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
*The [[incidence]] of polyarteritis nodosa is approximately 3 to 4 per 100,000 individuals worldwide.<ref name="pmid2562798">{{cite journal |vauthors=McMahon BJ, Heyward WL, Templin DW, Clement D, Lanier AP |title=Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up |journal=Hepatology |volume=9 |issue=1 |pages=97–101 |date=January 1989 |pmid=2562798 |doi= |url=}}</ref>
===Prevalence===
*The  [[prevalence]] among alaskan population suffering with [[hepatitis B]] infection is approximately 7.7 per 100,000 individuals.
===Age===
===Age===
The condition affects adults more frequently than children.
*Patients of all age groups may develop polyarteritis nodosa.
*Polyarteritis nodosa is mostly diagnosed in patients aged 45-65 years. <ref name="pmid16045832">{{cite journal |vauthors=Colmegna I, Maldonado-Cocco JA |title=Polyarteritis nodosa revisited |journal=Curr Rheumatol Rep |volume=7 |issue=4 |pages=288–96 |date=August 2005 |pmid=16045832 |doi= |url=}}</ref>
===Race===
*There is no racial predilection to polyarteritis nodosa.
===Gender===
*Males are more commonly affected by polyarteritis nodosa than females. The male to female ratio is approximately 1.5 to 1.
 
=== Region ===
* Population prevalence estimates for polyarteritis nodosa (PAN) range from 2 to 33 per million across the European Countries. <ref name="pmid17553910">{{cite journal| author=Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M| title=Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. | journal=Rheumatology (Oxford) | year= 2007 | volume= 46 | issue= 8 | pages= 1329-37 | pmid=17553910 | doi=10.1093/rheumatology/kem107 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17553910  }} </ref>
 
* The annual incidence in three regions of Europe was estimated to be 4.4 to 9.7 per million <ref name="pmid10693883">{{cite journal| author=Watts RA, Lane SE, Bentham G, Scott DG| title=Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. | journal=Arthritis Rheum | year= 2000 | volume= 43 | issue= 2 | pages= 414-9 | pmid=10693883 | doi=10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10693883  }} </ref>.


==References==
==References==
{{reflist|2}}
{{reflist|2}}
[[Category:Needs content]]
 
{{WH}}
{{WS}}

Latest revision as of 14:10, 11 May 2018

Polyarteritis nodosa Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polyarteritis nodosa from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiography

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polyarteritis nodosa epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polyarteritis nodosa epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polyarteritis nodosa epidemiology and demographics

CDC on Polyarteritis nodosa epidemiology and demographics

Polyarteritis nodosa epidemiology and demographics in the news

Blogs on Polyarteritis nodosa epidemiology and demographics

Directions to Hospitals Treating Polyarteritis nodosa

Risk calculators and risk factors for Polyarteritis nodosa epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Sargun Singh Walia M.B.B.S.[3]

Overview

The incidence of polyarteritis nodosa is approximately 3 to 4 per 100,000 individuals worldwide.The prevalence among alaskan population suffering with hepatitis B infection is approximately 7.7 per 100,000 individuals.Patients of all age groups may develop polyarteritis nodosa.There is no racial predilection to polyarteritis nodosa.Males are more commonly affected by polyarteritis nodosa than females.Population prevalence estimates for polyarteritis nodosa (PAN) range from 2 to 33 per million across the European Countries.

Epidemiology and Demographics

Incidence

  • The incidence of polyarteritis nodosa is approximately 3 to 4 per 100,000 individuals worldwide.[1]

Prevalence

  • The prevalence among alaskan population suffering with hepatitis B infection is approximately 7.7 per 100,000 individuals.

Age

  • Patients of all age groups may develop polyarteritis nodosa.
  • Polyarteritis nodosa is mostly diagnosed in patients aged 45-65 years. [2]

Race

  • There is no racial predilection to polyarteritis nodosa.

Gender

  • Males are more commonly affected by polyarteritis nodosa than females. The male to female ratio is approximately 1.5 to 1.

Region

  • Population prevalence estimates for polyarteritis nodosa (PAN) range from 2 to 33 per million across the European Countries. [3]
  • The annual incidence in three regions of Europe was estimated to be 4.4 to 9.7 per million [4].

References

  1. ↑ McMahon BJ, Heyward WL, Templin DW, Clement D, Lanier AP (January 1989). "Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up". Hepatology. 9 (1): 97–101. PMID 2562798.
  2. ↑ Colmegna I, Maldonado-Cocco JA (August 2005). "Polyarteritis nodosa revisited". Curr Rheumatol Rep. 7 (4): 288–96. PMID 16045832.
  3. ↑ Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M (2007). "Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden". Rheumatology (Oxford). 46 (8): 1329–37. doi:10.1093/rheumatology/kem107. PMID 17553910.
  4. ↑ Watts RA, Lane SE, Bentham G, Scott DG (2000). "Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom". Arthritis Rheum. 43 (2): 414–9. doi:10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0. PMID 10693883.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Polyarteritis_nodosa_epidemiology_and_demographics&oldid=1470081"